Sphera Funds Management LTD. lifted its position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) by 191.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,522 shares of the company’s stock after acquiring an additional 20,694 shares during the period. Sphera Funds Management LTD.’s holdings in Eidos Therapeutics were worth $315,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Flinton Capital Management LLC acquired a new stake in shares of Eidos Therapeutics during the 2nd quarter valued at approximately $110,000. Point72 Hong Kong Ltd acquired a new stake in shares of Eidos Therapeutics during the 2nd quarter valued at approximately $111,000. Tiverton Asset Management LLC acquired a new stake in shares of Eidos Therapeutics during the 2nd quarter valued at approximately $163,000. Bank of New York Mellon Corp acquired a new stake in shares of Eidos Therapeutics during the 3rd quarter valued at approximately $137,000. Finally, Northern Trust Corp bought a new position in Eidos Therapeutics during the 2nd quarter worth $281,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Bridgebio Pharma Llc acquired 2,853,848 shares of the stock in a transaction that occurred on Wednesday, December 5th. The stock was purchased at an average cost of $14.92 per share, for a total transaction of $42,579,412.16. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
A number of research analysts recently commented on EIDX shares. Zacks Investment Research downgraded Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 17th. Leerink Swann started coverage on Eidos Therapeutics in a research note on Tuesday, November 27th. They set an “outperform” rating and a $32.00 price objective for the company. Bank of America lowered their price objective on Eidos Therapeutics from $24.00 to $13.00 and set a “neutral” rating for the company in a research note on Monday, October 1st. Finally, Roth Capital started coverage on Eidos Therapeutics in a research note on Wednesday, October 31st. They set a “buy” rating and a $28.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $28.20.
Shares of EIDX opened at $13.15 on Friday. Eidos Therapeutics Inc has a 12 month low of $8.89 and a 12 month high of $24.75.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.02). Equities analysts predict that Eidos Therapeutics Inc will post -1.99 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/12/08/sphera-funds-management-ltd-boosts-position-in-eidos-therapeutics-inc-eidx.html.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Further Reading: How to use beta for portfolio diversification
Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.